STAT1
STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
Overview
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signalling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerise and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Cisplatin and Picoplatin. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.87, animal model 0.54, genetic association 0.03).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
- 1 · What it is
STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
- 2 · What goes wrong in cancer
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors.
- 3 · How drugs use it
No product in this corpus aims at STAT1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11362 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42224 (protein name, function text, keywords and locations (REST API)); CIViC gene STAT1 (2 evidence items, 0 assertions, 2 variants; diseases: Melanoma, Ovarian Cancer (GraphQL API, CC0)); Open Targets ENSG00000115415 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Biology
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signalling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerise and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Location: Cytoplasm; Nucleus (UniProt). Locus 2q32.2 (HGNC).
- Ovarian cancer: CIViC evidence names this disease
- Melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"STAT1" OR ABSTRACT:"STAT1" OR TITLE:"signal transducer and activator of transcription 1" OR ABSTRACT:"signal transducer and activator of transcription 1" OR TITLE:"Signal transducer and activator of transcription 1-alpha/beta" OR ABSTRACT:"Signal transducer and activator of transcription 1-alpha/beta" OR TITLE:"STAT91" OR ABSTRACT:"STAT91" OR TITLE:"ISGF-3" OR ABSTRACT:"ISGF-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetB2M
Shares Antigen presentation & immune editing, CIViC, Melanoma, Open Targets Platform.
- TargetSTAT3
Shares JAK-STAT signalling, CIViC, Ovarian cancer, Open Targets Platform.
- TargetJAK1
Shares JAK-STAT signalling, Antigen presentation & immune editing.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
- Targetgp100 (PMEL)
- TargetPRAME
Shares Antigen presentation & immune editing, Ovarian cancer, Melanoma.
- TargetMAGE-A4
- TermHLA-A*02:01 restriction